Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

U.S. Retinal Specialists Eagerly Await Pipeline GA Drugs

By R&D Editors | June 4, 2014

Decision Resources Group finds that surveyed U.S. retinal specialists are highly willing to prescribe key emerging therapies for the treatment of geographic atrophy (GA), the dry form of advanced age-related macular degeneration (AMD). In particular, clinicians expect to prescribe Roche/Genentech’s lampalizumab and Acucela/Otsuka’s emixustat, two mid-stage compounds, to a median 30% and 50% of their diagnosed GA patients, respectively. Respondents expect the other products queried—GlaxoSmithKline’s GSK-933776, Advanced Cell Technology’s MA09-hRPE cell transplantation and Alimera Sciences/pSivida’s Iluvien/Medidur (sustained-release fluocinolone acetonide)—to capture lower, but nonetheless meaningful, patient shares.
 
Other key findings from the DecisionBase report:
 
  • End point importance: While effect on GA area progression—an anatomic measure—is the primary end point in both completed and ongoing clinical trials of key emerging therapies, surveyed U.S. and European retinal specialists indicate a greater likely importance of a drug’s demonstrated effect on visual acuity—a familiar clinical metric—in future prescribing decisions for GA. 
  • Delivery as a differentiator: Part-worth utilities derived from a conjoint study reveal that, to surveyed U.S. retinal specialists, the attractiveness of a GA therapy is not heavily influenced by any one specific dosing frequency or unique formulation among a broad range presented. These data correlate with the responses of surveyed U.S. and European retinal specialists, who identify infrequent dosing or convenient delivery as areas of moderate opportunity for therapy differentiation. 
  • The payer perspective: Surveyed U.S. managed care organization pharmacy directors are receptive to reimbursing GA therapies—75% of surveyed U.S. payers indicated high or very high willingness to grant favorable formulary status to GA therapies demonstrated to maintain visual acuity. Moreover, would-be reimbursers accepted a high yearly cost for emerging therapies demonstrating a reduction in GA area progression. This cost was comparable to that of branded agents used in the treatment of the wet form of advanced AMD.
 
Comments from Decision Resources Group Analyst Nadja Rozovsky, Ph.D.:
 
  •  “Although limited clinical trial data are available to support the efficacy and safety of pipeline agents, the need for GA therapies where none are currently approved drives the high level of physician willingness to prescribe the emerging treatments profiled to their GA patients once they become available.” 
  • “Generally speaking, both U.S. payers and retinal specialists appear ready to embrace future high-cost GA drugs, suggesting a smooth path to market entry and potentially strong uptake for the first agents approved for this highly underserved patient population.”
 
Date: June 4, 2014
Source: Decision Resources Group

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE